# A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients

> **NCT06548854** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Grand Medical Pty Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** STC314 Injection/STC314 Injection Placebo

## Key facts

- **NCT ID:** NCT06548854
- **Lead sponsor:** Grand Medical Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-02-28
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548854, "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06548854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*